Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


Octet® HTX System

Product Image
Product Description

The Octet HTX instrument monitors up to 96 biosensors simultaneously, enabling label-free detection for protein quantitation and kinetic characterization at unmatched speed. The system's ability to read 8, 16, 32, 48 or 96 wells in parallel lets you tailor your assay design to maximize analytical throughput or sensitivity. Rapid whole-plate detection is accomplished using the 96 biosensor mode, providing either quantitation data for 96 samples in as little as 2 minutes or full plate kinetic screening in minutes instead of hours. The 8 and 16 biosensor modes provide high sensitivity for measuring small molecule binding interactions and protein quantitation down to 50 ng/mL. The 32 or 48 biosensor modes enable larger complex assays such as epitope binning or multi-step quantitation to be analyzed in the shortest amount of time. Key applications that leverage the unique strengths of the Octet HTX system include epitope binning experiments, off-rate ranking, and titer concentration.

Key Features

The Octet HTX system offers unmatched performance, flexibility and throughput.
•    Up to 96-well simultaneous sampling
•    384-well and 96-well formats
•    Quantitate 96 samples in as little as two minutes
•    Two plate locations maximize throughput and improve workflow
•    Automation friendliness allows multiple-plate assays in one run
•    Biosensor re-racking allows maximum flexibility and operational cost savings
•    Advanced software tools for epitope binning analysis

Product Octet® HTX System
Company ForteBio
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

ForteBio
Menlo Science & Technology Park 1360 Willow Road, Suite 201 Menlo Park, CA 94025 USA

Tel: 650.322.1360
Fax: Fax: 650.322.1370
Email: fortebio_info@pall.com



Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.

SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!